Douglas W. Pagan - Jun 15, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Signature
/s/ Douglas Fambrough, attorney-in-fact
Stock symbol
DRNA
Transactions as of
Jun 15, 2021
Transactions value $
-$71,623
Form type
4
Date filed
6/17/2021, 09:37 PM
Next filing
Dec 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRNA Common Stock Options Exercise +6.83K +726.84% 7.76K Jun 15, 2021 Direct F1, F2
transaction DRNA Common Stock Tax liability -$71.6K -2K -25.81% $35.74 5.76K Jun 15, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRNA Restricted Stock Units Options Exercise $0 -6.83K -25% $0.00 20.5K Jun 15, 2021 Common Stock 6.83K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2 Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).
F3 Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F4 Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.